Phenomix Corp.: Series C $55M

Phenomix (San Diego, Calif.) a drug discovery and development company focused on the treatment of Type 2 diabetes and hepatitis C raised a $55M Series C financing. The deal was led by Nomura Phase4 and joined by JPMorgan, Delphi Ventures, Baker Brothers, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, Novartis Venture Fund and GBS Venture Partners.

Intarcia Therapeutics, Inc.: Series B $50M

Intarcia Therapeutics (Emeryville, CA) a biopharmaceutical company developing therapies for Type 2 Diabetes and Hepatitis C raised $50M in a Series BB Financing. The round was led by New Leaf Venture, and joined by Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, and Granite Global Ventures.

Phenomix, Inc.: Series C $55M

Phenomix (San Diego, CA) a drug discovery and development company focused on novel drugs to inhibit therapeutic targets in the protease and kinase families.The most advanced programs are for treatment of Type 2 diabetes and for treatment of hepatitis C. The deal was led by Nomura Phase4 Ventures and was joined by JP Morgan Partners, Delphi Ventures, Baker Brothers Life Sciences Capital, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, Novartis Venture Fund and GBS Venture Partners.

Avestha Technologies Ltd.: Series C €25M

Avestha (India) developer of bioactive nutraceuticals closed a €25M Series C financing. The round was led by Fidelity International, Limagrain Group (France), Danone Group (France) and Bennett, Coleman (India).

InteKrin Therapeutics, Inc.: Series B $23M

InteKrin Therapeutics (Palo Alto, CA) a clinical stage biopharmaceutical company focused on products for diabetes, metabolism and obesity has secured $23M in Series B funding. The financing was led by Sofinnova Ventures and included Orbimed Advisors, Vivo Ventures, and return backer Sears Capital Management.